RestructuringAug 7, 2026, 04:59 PM
Wave Life Sciences Completes Redomiciliation to Delaware
AI Summary
Wave Life Sciences Ltd. completed its redomiciliation, making Wave Life Sciences, Inc., a Delaware corporation, the new ultimate parent company. All ordinary shares of the Singapore entity were exchanged on a one-for-one basis for common stock of the Delaware entity. The Singapore entity's shares will be delisted from Nasdaq, and the Delaware entity's common stock will begin trading under the same 'WVE' symbol on August 10, 2026. The company also entered into indemnification agreements with its directors and executive officers and assumed the 2014 Equity Incentive Plan.
Key Highlights
- Wave Life Sciences Ltd. (Singapore) redomiciled to Wave Life Sciences, Inc. (Delaware).
- All Wave-Singapore ordinary shares exchanged one-for-one for Wave-Delaware common stock.
- Wave-Singapore shares will be delisted from Nasdaq prior to August 10, 2026.
- Wave-Delaware common stock will begin trading on Nasdaq under 'WVE' on August 10, 2026.
- Wave-Delaware is now the successor issuer, subject to Exchange Act reporting requirements.
- Wave-Delaware entered into indemnification agreements with its directors and executive officers.
- Wave-Delaware assumed the 2014 Equity Incentive Plan.
- Directors and executive officers of Wave-Singapore became those of Wave-Delaware.
Price Impact
More from WVE